Regenxbio Inc (RGNX)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Regenxbio Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 8 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 10.00 $ — 42% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
3/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 49.4%
- Exp. sales growth 3Y > 5% 20.5%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 20.5%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 2
- Max. EBIT decline < 50% 100.0%
- Return on equity > 15% -188.7%
- ROCE > 15% -48.1%
- Expected return > 10% -9.8%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
3 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 14.8% failed
- More than 10% revenue growth is expected for the coming year 14.6% passed
- Share count grows by less than 3% a year 6.1% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 30.4% failed
- Gross margin at 40% or higher and without meaningful erosion 88.1% passed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA failed
- Operating cash flow covers the profits of the last three years 169 m failed
- Return on capital at 15% or higher, or up versus two years ago -48.1% failed
- Insiders hold at least 10% or are net buyers 8.1% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 142.7% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 12
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -2.79 | -4.91 – 1.61 | 238 | 25.8% | 8 |
| 12/31/2027 | -2.54 | -4.58 – -0.24 | 248 | 8.9% | 7 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.12 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -1.01 | – | 21 | -4.50 | -241.30 | -32 | -33 |
| 2025: Q1 | 0.12 | – | 89 | 469.80 | 6.80 | 34 | 33 |
| 2025: Q2 | -1.38 | – | 21 | -4.20 | -331.80 | -49 | -50 |
| 2025: Q3 | -1.20 | – | 30 | 22.90 | -208.30 | -56 | -57 |
| 2025: Q4 | -1.30 | – | 30 | 43.00 | -221.30 | -52 | -53 |
| 2026: Q1 | -1.72 | -1,552.30 | 6 | -92.80 | -1,408.60 | -76 | -77 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 5 | -65 | -63 | -2.38 | -49 | 162 | 173 |
| 2017 | 10 | -76 | -73 | -2.45 | -58 | 183 | 199 |
| 2018 | 219 | 88 | 100 | 2.73 | 105 | 509 | 544 |
| 2019 | 35 | -149 | -95 | -2.58 | -108 | 450 | 498 |
| 2020 | 155 | -119 | -111 | -2.98 | -54 | 378 | 708 |
| 2021 | 470 | 160 | 128 | 2.91 | 219 | 764 | 1,114 |
| 2022 | 113 | -263 | -280 | -6.50 | -207 | 516 | 833 |
| 2023 | 90 | -268 | -263 | -6.02 | -218 | 312 | 574 |
| 2024 | 83 | -233 | -227 | -4.59 | -173 | 260 | 466 |
| 2025 | 170 | -161 | -194 | -3.76 | -124 | 103 | 453 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
REGENXBIO Inc. , a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.
| Employees | 371 |
|---|---|
| Headquarters | Rockville, MD |
| Address | 9804 Medical Center Drive, 20850 Rockville, United States |
| Phone | 240 552 8181 |
| Website | regenxbio.com |
| IPO Date | 17. Sep 2015 |
| ISIN | US75901B1070 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Curran M. Simpson M.S. | President, CEO & Director | 1962 |
| Patrick J. Christmas II, J.D. | Executive VP & Chief Strategy and Legal Officer | 1971 |
| Stephen Pakola M.D. | Executive VP & Chief Medical Officer | 1969 |
| Mitchell Chan M.B.A. | Executive VP & CFO | 1981 |
| Craig Malzahn | Executive VP of Product Development & CTO | 1973 |
| Olivier Danos Ph.D. | Executive VP & Chief Scientific Officer | 1958 |
| Shiva G. Fritsch | Chief Communications & People Officer | – |
| Ram Palanki Pharm.D. | Executive VP & Chief Commercial Officer | 1976 |
| Nina Hunter | SVP of Global Regulatory Strategy and Quality | – |
| Jahannaz Dastgir D.O. | Clinical Development Lead | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.